CareDx Announces New $50 Million Stock Repurchase

CareDx ( (CDNA) ) just unveiled an update.

On May 30, 2025, CareDx‘s Board of Directors authorized a new $50 million stock repurchase program to be executed over the next 24 months, following the completion of a previous $50 million repurchase. This decision comes after CareDx completed the repurchase of approximately 5% of its outstanding shares, reflecting the company’s strong financial position with $231 million in cash and no debt. The repurchase is part of CareDx’s strategy to return value to shareholders while continuing to invest in growth and innovation, as evidenced by their seventh consecutive quarter of testing services volume growth and an 18% year-over-year increase in first-quarter revenue.

The most recent analyst rating on (CDNA) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on CareDx stock, see the CDNA Stock Forecast page.

Spark’s Take on CDNA Stock

According to Spark, TipRanks’ AI Analyst, CDNA is a Outperform.

CareDx’s strong financial performance and positive earnings call sentiment drive its score, highlighting solid revenue and profit growth. Despite technical analysis indicating potential resistance levels, the company’s valuation remains attractive, supporting its growth prospects. Challenges from past financial volatility and recent legal settlements require monitoring but do not overshadow the positive outlook.

To see Spark’s full report on CDNA stock, click here.

More about CareDx

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. The company offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients.

Average Trading Volume: 1,000,487

Technical Sentiment Signal: Sell

Current Market Cap: $951M

Find detailed analytics on CDNA stock on TipRanks’ Stock Analysis page.